Pérez-Stachowski, JavierTortajada, BegoñaDel Arco, AlfonsoMárquez, EfrénDe la Torre, JavierNieto, MiriamGarcía de Lomas, José MaríaPrada, José LuisGarcía-Alegría, JavierOlalla, Julián2025-01-072025-01-072019-07-05https://hdl.handle.net/10668/26684Introduction: Generic drugs are helpful to enhance the efficiency of the sanitary system. A generic coformulation of abacavir (ABC) and lamivudine (3TC) is available since 2016 in Spain. A report of our experience with its use is exposed. Methods: Patients between February 2017 and June 2017 who were taking Triumeq® were switched to the generic ABC + 3TC plus DTG. Efficacy, safety, reasons for discontinuation and costs savings were evaluated at 48 weeks. Results: Switch was made in 93 patients, with a median age of 47 years and a mean time of 12.33 years with HIV infection. Six patients (6.5%) discontinued the new ART, being toxicity of the central nervous system the most frequent reason. The effective saving derived from the change after 1 year of treatment was 151.127 €. Conclusions: The change from Triumeq® to a generic regimen of ABC + 3TC and another pill of DTG seems to be safe and efficient at 48 weeks.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/DolutegravirHIVantiretroviral treatmentdrugsgenericswitchAnti-HIV AgentsDideoxynucleosidesDrug CombinationsDrug SubstitutionDrugs, GenericFemaleHIV InfectionsHeterocyclic Compounds, 3-RingHumansLamivudineMaleMiddle AgedRetrospective StudiesSpainresearch article31272264open access10.1080/23744235.2019.16375362374-4243https://europepmc.org/articles/pmc6180504?pdf=render